Admescope — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Admescope, founded in 2011 and rebranded under its current name, is a specialized Finnish preclinical CRO focused on ADME-Tox and in vivo DMPK (Drug Metabolism and Pharmacokinetics) studies. It serves a global clientele of biotech and pharmaceutical companies with flexible, high-quality research services, leveraging a skilled team and continuous R&D investment. As a subsidiary of Symeres since 2020, it benefits from broader integrated drug discovery capabilities while maintaining its core expertise in metabolism and bioanalysis. The company is a revenue-generating service provider in the growing outsourced preclinical research market.

Drug DeliverySmall Molecules

Technology Platform

A suite of analytical and biological assay services for preclinical ADME-Tox and DMPK studies, specializing in drug metabolism, drug interactions, pharmacokinetics, and quantitative bioanalysis for all drug modalities (small molecules, peptides, oligonucleotides, antibodies, ADCs).

Opportunities

The growing trend of pharmaceutical and biotech companies outsourcing specialized preclinical work presents a major opportunity.

Expansion into supporting complex new drug modalities (e.g., oligonucleotides, ADCs) and leveraging the integrated service portfolio of parent company Symeres for cross-selling are key growth drivers.

Risk Factors

High competition in the CRO market, dependence on the R&D spending cycles of client companies, and the critical need to maintain flawless data quality and project execution to protect reputation.

Retention of specialized scientific talent is also a key operational risk.

Competitive Landscape

Admescope competes in the global preclinical CRO market against large, full-service players (e.g., LabCorp, Charles River) and numerous niche ADME/DMPK specialists. Its differentiation lies in its deep metabolism expertise, flexibility, modality-agnostic services, and integration with Symeres's chemistry capabilities.

More companies in Diagnostics & Precision Medicine →More companies in Finland →